سعر اموسار فورت 100/25 مجم 30 قرص 2024

Losartan potassium 100 mg + hydrochlorothiazide 25 mg film-coated tablets, pack of 30 (3 strips); fixed-dose antihypertensive combination.

• Treatment of hypertension when combination therapy is appropriate (not indicated for initial therapy except in severe hypertension)Population: AdultsDailyMed (U.S. National Library of Medicine)
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy (evidence does not apply to Black patients)Population: AdultsDailyMed (U.S. National Library of Medicine)

• Adverse reactions more frequent than placebo in hypertension trials include dizziness (5.7%), upper respiratory infection (6.1%) and back pain (2.1%); hypokalemia (serum potassium below 3.5 mEq/L) occurred in 6.7% of patients with the combination.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Postmarketing: hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer (predominantly squamous cell carcinoma, in white patients taking large cumulative doses); patients should protect skin from the sun and undergo regular skin-cancer screening. Angioedema, vasculitis, anaphylactic reactions and rhabdomyolysis have also been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to any component of the product; anuria.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Co-administration with aliskiren in patients with diabetes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - fetal toxicity: discontinue as soon as possible when pregnancy is detected; drugs acting on the renin-angiotensin system can cause fetal injury and death.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypotension in volume- or salt-depleted patients; changes in renal function; hypersensitivity reactions to hydrochlorothiazide.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Electrolyte and metabolic effects: hydrochlorothiazide can cause hypokalemia, hyponatremia and hypomagnesemia, while losartan can cause hyperkalemia; hydrochlorothiazide may alter glucose tolerance, raise cholesterol and triglycerides, precipitate hyperuricemia/gout and raise serum calcium - monitor electrolytes and calcium periodically. Acute myopia and secondary angle-closure glaucoma (hydrochlorothiazide); exacerbation or activation of systemic lupus erythematosus.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Agents increasing serum potassium (potassium-sparing diuretics, potassium supplements, salt substitutes)May increase serum potassium; monitor potassium.DailyMed (U.S. National Library of Medicine)
• LithiumIncreases in serum lithium concentrations and lithium toxicity have been reported; monitor lithium levels.DailyMed (U.S. National Library of Medicine)
• NSAIDs including selective COX-2 inhibitorsMay cause deterioration of renal function (including acute renal failure) in elderly, volume-depleted or renally impaired patients and may attenuate the antihypertensive effect; monitor renal function.DailyMed (U.S. National Library of Medicine)

• Drugs acting on the renin-angiotensin system in the second and third trimesters reduce fetal renal function and increase fetal and neonatal morbidity and death; thiazides cross the placenta and may cause fetal or neonatal jaundice, thrombocytopenia and other adverse reactions. Discontinue when pregnancy is detected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Thiazides appear in human milk; it is not known whether losartan is excreted in human milk. Because of potential adverse effects on the nursing infant, decide whether to discontinue nursing or the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Losartan: Losartan and its principal active metabolite selectively block binding of angiotensin II to the AT1 receptor, blocking its vasoconstrictor and aldosterone-secreting effects (US label).
• Hydrochlorothiazide: Promotes renal excretion of sodium and chloride, reducing intravascular volume.